Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.

about

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.

Item

http://www.wikidata.org/entity/Q41437605

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Intercalating and maintenance ...... ncer with unknown EGFR status.

@en

type

Item

label

Intercalating and maintenance ...... ncer with unknown EGFR status.

@en

prefLabel

Intercalating and maintenance ...... ncer with unknown EGFR status.

@en

P1476

Intercalating and maintenance ...... ncer with unknown EGFR status.

@en

P2093

Beili Gao

http://www.w3.org/2001/XMLSchema#string

Chong Bai

http://www.w3.org/2001/XMLSchema#string

Dong Hua

http://www.w3.org/2001/XMLSchema#string

Hong Jian

http://www.w3.org/2001/XMLSchema#string

Hongming Pan

http://www.w3.org/2001/XMLSchema#string

Huili Zhu

http://www.w3.org/2001/XMLSchema#string

Jianjin Huang

http://www.w3.org/2001/XMLSchema#string

Jifeng Feng

http://www.w3.org/2001/XMLSchema#string

Min Tao

http://www.w3.org/2001/XMLSchema#string

Shenglin Ma

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Global cancer statistics, 2012

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

P2888

s41598-017-08399-8

P304

8483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-08399-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091148306

http://www.w3.org/2001/XMLSchema#string

P698

28814805

http://www.w3.org/2001/XMLSchema#string

P932

5559626

http://www.w3.org/2001/XMLSchema#string